Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4870615
Max Phase: Preclinical
Molecular Formula: C20H19F2N7
Molecular Weight: 395.42
Molecule Type: Unknown
Associated Items:
ID: ALA4870615
Max Phase: Preclinical
Molecular Formula: C20H19F2N7
Molecular Weight: 395.42
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CCc1cc(Nc2nc(N[C@@H](C)c3ccc(F)cn3)nc3cccc(F)c23)n[nH]1
Standard InChI: InChI=1S/C20H19F2N7/c1-3-13-9-17(29-28-13)26-19-18-14(22)5-4-6-16(18)25-20(27-19)24-11(2)15-8-7-12(21)10-23-15/h4-11H,3H2,1-2H3,(H3,24,25,26,27,28,29)/t11-/m0/s1
Standard InChI Key: HZHXOMKYANMUKK-NSHDSACASA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 395.42 | Molecular Weight (Monoisotopic): 395.1670 | AlogP: 4.51 | #Rotatable Bonds: 6 |
Polar Surface Area: 91.41 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 3 |
#RO5 Violations: 0 | HBA (Lipinski): 7 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 11.92 | CX Basic pKa: 5.15 | CX LogP: 4.67 | CX LogD: 4.67 |
Aromatic Rings: 4 | Heavy Atoms: 29 | QED Weighted: 0.45 | Np Likeness Score: -1.48 |
1. Uehling DE, Joseph B, Chung KC, Zhang AX, Ler S, Prakesch MA, Poda G, Grouleff J, Aman A, Kiyota T, Leung-Hagesteijn C, Konda JD, Marcellus R, Griffin C, Subramaniam R, Abibi A, Strathdee CA, Isaac MB, Al-Awar R, Tiedemann RE.. (2021) Design, Synthesis, and Characterization of 4-Aminoquinazolines as Potent Inhibitors of the G Protein-Coupled Receptor Kinase 6 (GRK6) for the Treatment of Multiple Myeloma., 64 (15.0): [PMID:34291633] [10.1021/acs.jmedchem.1c00506] |
Source(1):